Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Accounts Payables: 2010-2021

Historic Accounts Payables for Neurocrine Biosciences (NBIX) over the last 11 years, with Sep 2021 value amounting to $205.9 million.

  • Neurocrine Biosciences' Accounts Payables rose 20.76% to $205.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $205.9 million, marking a year-over-year increase of 20.76%. This contributed to the annual value of $168.7 million for FY2020, which is 19.39% up from last year.
  • Neurocrine Biosciences' Accounts Payables amounted to $205.9 million in Q3 2021, which was up 7.86% from $190.9 million recorded in Q2 2021.
  • Over the past 5 years, Neurocrine Biosciences' Accounts Payables peaked at $205.9 million during Q3 2021, and registered a low of $852,000 during Q1 2017.
  • Its 3-year average for Accounts Payables is $143.4 million, with a median of $141.3 million in 2019.
  • In the last 5 years, Neurocrine Biosciences' Accounts Payables crashed by 59.85% in 2017 and then skyrocketed by 5,257.98% in 2018.
  • Over the past 5 years, Neurocrine Biosciences' Accounts Payables (Quarterly) stood at $53.5 million in 2017, then spiked by 61.39% to $86.4 million in 2018, then spiked by 63.59% to $141.3 million in 2019, then rose by 19.39% to $168.7 million in 2020, then rose by 20.76% to $205.9 million in 2021.
  • Its Accounts Payables stands at $205.9 million for Q3 2021, versus $190.9 million for Q2 2021 and $171.9 million for Q1 2021.